Newave Pharmaceutical Inc clinical trials

A subsidiary of Lupeng Pharmaceutical Ltd.

The registry lists 4 studies whose lead sponsor is Newave Pharmaceutical Inc. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 11, 2026.

Status

Recruiting: 3
Completed: 1

Phase

Phase 1: 3
Phase 3: 1

Where

United States: 4
Spain: 1

Registry sponsor names on this page

Newave Pharmaceutical Inc4 studies

Something wrong with this grouping? Tell us on the Lupeng Pharmaceutical Ltd. page.

Studies

Recruiting first, then most recently updated. Showing 4 of 4. All Lupeng Pharmaceutical Ltd. studies →

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLRecruitingNCT07342478Phase 3
Sponsor listed in the registry: Newave Pharmaceutical Inc
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.RecruitingNCT04771572Phase 1
Sponsor listed in the registry: Newave Pharmaceutical Inc
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.RecruitingNCT04775745Phase 1
Sponsor listed in the registry: Newave Pharmaceutical Inc
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AMLCompletedNCT04139434Phase 1
Sponsor listed in the registry: Newave Pharmaceutical Inc